Michael David Lesem MD

Psychiatry•Houston, TX

Forensic Psychiatry, Geriatric Psychiatry, Neuropsychiatry, Psychopharmacology

Executive Medical Director CLRC, Ltd.

Join to View Full Profile

4306 Yoakum Blvd Ste 230Houston, TX 77006
Phone+1 832-538-1479
Fax+1 832-558-4440

Summary

I graduated from UT Medical School in 1981. I was recognized as Outstanding Student in Psychiatry in my class. I then did one year of Internal Medicine (Internship) at UT Southwestern affliated program. I returned to UT Houston Medical School to complete my 3 years training in psychiatry. Very neuroscience oriented program under Chairman Louis Faillace, MD. My last year I was Chief Resident and acted as junior faculty assisting Ken Reed MD, PhD in re-organizing the Consultation service to our main teaching hospital-Memorial Hermann. I received perhaps the best training possible in psychiatry through the UTMSH residency program under Dr. Faillace. I then was accepted for a 2 year Research Fellowship at NIMH in Bethesda under Dennis Murphy, MD and others such as Bill Potter, MD, PhD in the Laboratory of Clinical Sciences. 1 year on research ward implementing protocols in eating disorder patients, completed a protocol in age/sex/nml weight matched normals who underwent pre and post LP's following 5% weight loss over 6 weeks. Year 2 I help develop assay to measure CSF Dynorphin A1-8 under guidance of Wade Berretini MD, PHD. I returned to UT Houston as Asst. Prof. and ran acute research units at HCPC for 3 yrs. I entered private practice in late 1989 and began mainly as hospitalist. Jim Claghorn, MD asked me to work at his private research clinic, CRA, and I transitioned to full ownership in 1994. Renamed CRA-to CLRC, Ltd. Focus became inpatient early drug developement. We developed our own 24 bed free-standing research unit and 8000 sq. ft. outpt. research center owned by the clinic. We have been one of just 2 sites in first Qtc studies in 2nd generation antipsychotics. We also have a strong reputation in developing medications for psychotic agitation. Recently we have developed infusion capabilities with dedicated space and equipment. We have experience with P-50/MMN. Our staff prides itself on implementing cutting edge protocols. Current website being updated.

Education & Training

National Institute of Mental HealthFellowship, 1985 - 1987
University of Texas Health Science Center at HoustonChief Residency, Psychiatry, 1984 - 1985
University of Texas Health Science Center at HoustonResidency, Psychiatry, 1982 - 1985
St Paul's HospitalMedicine, 1981 - 1982
McGovern Medical School at UTHealthClass of 1981
University of TexasB.A, History, Cum Laude, 1976

Certifications & Licensure

TX State Medical License 1981 - 2026
WA State Medical License 2016 - 2018
MD State Medical License 1985 - 1988
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

Dean's Teaching Excellence List University of Texas Medical School, Houston, TX, 1987, 1988, 1989, 1990
Inpatient Teaching Award Psychiatry Residents, University of Texas Medical School, Houston, TX, 1989-1990, 1990
Resident's Service Award University of Texas Medical School, Houston, TX, 1988, 1989
Appointment, Chief Resident Department of Psychiatry, University of Texas Medical School, Houston, TX, 1984-1985, 1985
Hoffman-LaRoche Biologic Psychiatry Award for Outstanding Student in Psychiatry University of Texas Medical School Class of 1981, Houston, TX, 1981
Merit Scholarship 1978
Elected President, Phi Rho Sigma First Chapter at University of Texas Medical School, Houston, TX, 1978
Student Senate Committee Appointment 1976
B.A. History, Cum Laude University of Texas, Austin, TX, 1976
Advisory Boards-Medavante, Teva, Corcept. Consultant-Alexza, INC, Novartis, Dianippon-Sumitomo, GSK, Sanofi, BMS, Abbott, Pharmacia, Wyeth, Pharmastar/UBC
Join now to see all

Clinical Trials

Treatment-Resistant Depression Registry Start of enrollment: 2006 Jan 01
Completed
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression Start of enrollment: 2011 May 01
Completed
Phase 2
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Start of enrollment: 2011 Jan 17
Completed
Phase 3
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Start of enrollment: 2013 Oct 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

113 citations
Vagus Nerve Stimulation Therapy Randomized to Different Amounts of Electrical Charge for Treatment-Resistant Depression: Acute and Chronic Effects
Scott Aaronson, Linda L. Carpenter, Charles R. Conway, Frederick W. Reimherr, Sarah H. Lisanby
Brain Stimulation. 2013-07-01
67 citations
Efficacy and Safety of Loxapine for Inhalation in the Treatment of Agitation in Patients With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
Michael H. Allen, David Feifel, Michael D. Lesem, Daniel L. Zimbroff, Ruth Ross
The Journal of Clinical Psychiatry. 2011-01-25
88 citations
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine.
Michael D. Lesem, Tram K. Tran-Johnson, Robert A. Riesenberg, David Feifel, Michael H. Allen
The British Journal of Psychiatry. 2011-01-01

Journal Articles

Repercussions of Redefining a Consultation-Liaison Service in a General Teaching Hospital.
Reed, K., Lesem, M. D., and O'Malley, M, Letter of Hospital and Community Psychiatry, 38:673-674
Enhanced Thermic Effect of Food after Exercising During Refeeding of Anorexic Patients.
Obarzanek, E. O., Lesem, M. D., and Jimerson, D. C, Proceedings of the Annual Meeting of FASEB: 2:A1224
Gender Differences and the Interpretation of Genetic Instability in Alzheimer's Disease.
Cherry, L. M., Funk, J., Lesser, J. M., Lesem, M. D, Mutation Research. 275, 57-67

Books/Book Chapters

Serotonin in Human Eating Disorders - a chapter in the Neuropharmacology of Serotonin.
Jimerson, D. C., Lesem, M. D., Hegg, A. P., and Brewerton, T. DEditors: Whitaker-Azmitia, P. M. and Peroutka, S.J.
Serotonin in Eating Disorders - a chapter in Serotonin in Major psychiatric Disorders.
Brewerton, T. D., Brandt, H. A., Lesem, M. D., Murphy, D. L., and Jimerson, D. CEditors: Cocarro, E. F. and Murphy, D. L.

Abstracts/Posters

Impulsivity in Bulimia. A Serotonin Connection.
Walton, B. C., Jimerson, D. C., Lesem, M. D., Franko, D., Leirne, J. M., Covino, N. A, 144th Annual Meeting American Psychiatric Association: NR:121
Neurotransmitter Function in Major Depression and Eating Disorders.
Jimerson, D. C., Lesem, M. D., Hegg, A. P., and Brandt, H. A, Regional Congress on Biological Aspects of Non-Psychotic Disorders, World Federation of Societies of Biological Psychiatry
Serotonin and human eating disorders.
Jimerson, D. C., Lesem, M. D., Hegg, A. P., Brewerton, T. D, Proceeds The New York Academy of Sciences Conference on Neuropharmacology of Serotonin
CSF 5-HIAA and HVA alterations in bulimia: relationship to plasma estradiol levels.
Jimerson, D. C., Lesem, M. D., Seibel, M. M., Brewerton, T. D, Proceeds ACNP: 28:192
Reduced Metabolic Rate in Bulimia Nervosa: Effect of Dietary Stabilization.
Jimerson, D. C., Obarzanek, E., Lesem, M. D., Piggott, T. A., and Brandt, H. A, Biological Psychiatry Vol. 25 No. 7a Suppl. pgs. 18a-19a
Dysregulation of 5-HYT function in bulimia nervosa: relationship to anorexia nervosa and major depression.
Brewerton, T. D., Brandt, H. A., Lesem, M. D., Hegg, A. P., Murphy, D. L. and Jimerson, D. C, Regional Congress on Biological Aspects of Nonpsychotic Disorders, World Fed. of Societies of Biol. Psychiatry
Sodium Valproate Treatment of Bipolar Patients.
Clothier, J. C., Freeman, T., Pazzaglia, P., Lesem, M. D., and Swan, A, 142nd Annual Meeting of the American Psychiatric Association: NR:216
Plasma and Cerebral Fluid Abnormalities of Arginine Vasopressin Secretion in Patients with Bulimia Nervosa.
Demitrack, M. A., Lesem, M. D., Kalogeras, K., Brandt, H. A., Granger, L., Gold, P. W, Proceedings ACNP
CSF Immunoreactive - TRH Levels in Anorexia.
Lesem, M. D., Kaye, W. H., Bissette, G., Jimerson, D. C., and Nemeroff, C. B, 143rd Annual Meeting American Psychiatric Association: NR:504
Valproate in Mania: A Double Blind Study.
Freeman, T. W., Clothier, J. L., Pazzaglia, P., Lesem, M. D., Swann, A. C., and Roache, A, 143rd Annual Meeting American Psychiatric Association; NR:393
Serotonin and Symptom Severity in Eating Disorders.
Jimerson, D. C., Lesem, M. D., Kaye, W. H., Hegg, A. P., and Brewerton, T. D, Biological Psychiatry Vol. 25 No. 7a Suppl. Page 141a
Symptom chronicity and neurotransmitters in bulimia.
Jimerson DC, Lesem MD, Brewerton TD, Walton BE, Am Psychiatr Assoc Annual Mtg Proceedings; 145:139
CSF and plasma tryptophan levels in bulimia nervosa and controls.
Walton BE, Jimerson DC, Lesem, MD, Am Coll Neuropsychopharmacology Annual Mtg Prog; 31:158
Serotonin function in bulimia nervosa: Influence of plasma tryptophan.
Walton BE, Jimerson DC, Lesem, MD, Brewerton TD, Clin Neuropharmacol;15 (suppl 1B):549B
Plasma HVA and dopamine function in patients with bulimia nervosa.
Jimerson DC, Beyer LC, Lesem MD, Clin Neuropharmacol; 15(suppl 1B):548B
The role of central catecholaminergic pathways in eating disorders.
Jimerson DC, Lesem MD, Beyer LC, Neuroendocrinology Letters; 14:186
Dopamine function in patients with bulimia: Comparison of HVA concentrations in plasma and CSF.
Jimerson DC, Beyer LC, Lesem MD, Biol Psychiatry; 31:139A
Efficacy and Safety of a Novel Long-Acting Risperidone Formulation.
Kane, J., Eerdekens, M., Keith, S., Lesem, M., Karcher, K., and Lindenmayer, JP, ACNP 2001 Annual Meeting
Plasma Level Response Characteristics of Valproate in the Treatment of Manic Syndrome.
Clothier, J. L., Pazzaglia, P. J., Freeman, T. W., Lesem, M. D., Swann, A. C, Annals of Clinical Psychiatry. Vol. 3, pp 321-324
Dysregulation of 5-HT Function in Bulimia Nervosa.
Brewerton, T. D., Mueller, E. A., Brandt, H. A., Lesem, M. D., Murphy, D. L., and Jimerson, D. C, Proceedings of the 141st Annual Meeting American Psychiatric Association: NR:304
Decrease in Plasma Norepinephrine Following Nutritional Stabilization in Underweight Patient with Anorexia Nervosa.
Lesem, M.D., George, D. T., Kaye, W. H., Brewerton, T. D., Brandt, H. A., Goldstein, D., and Jimerson, D. C, Fifteenth C.I.N.P. Congress
Blunted Prolactin Response to m-CPP in Bulimia.
Brewerton, T.D., Mueller, E.Z., George, D. T., Brandt, H. A., Lesem, M.D., Narang, P., Jimerson, D. C., and Murphy, D. L, Fifteenth C.I.N.P. Congress
Relationship Between CSF CRH and MHPG in Anorexia Nervosa.
Lesem, M. D., Gold, P. W., Hegg, A. P., and Jimerson, D. C, 141st Annual Meeting American Psychiatric Association: NR:271 2988
Resting Metabolic Rate During Weight Gain in Anorexia Nervosa.
Obarzanek, E. O., Lesem, M. D., and Jimerson, D. C, Fed. Proceed. 46:1336
Neuroendocrine studies with 5 HT agents in bulimia.
Brewerton TD, Mueller EA, Brandt HA, Lesem MD, Jimerson DC, Murphy DL, Am Psychiatric Association Annual Meeting Proceedings; 140:85-86 #38E
Join now to see all

Lectures

Bulimia Nervosa - Overview with Emphasis on Biology and Hospital Treatment.
UTMSH, Department of Psychiatry, PGYII Lecture Series, 1988, 1989, 1990
Overview of Bulimia Nervosa.
UTMSH, Department of Psychiatry, MSII Behavioral Science Course, 1988, 1989, 1990
Overview of Neuroendocrine System and Psychiatric Illness.
UTMSH, Department of Psychiatry, MSII Behavioral Science Course, 1988, 1989, 1990
Evaluation of the ER Patient.
UTMSH, Department of Psychiatry, PGYI Lecture Series, 1988, 1989, 1990
Catatonia.
UTMSH, Department of Psychiatry, PGYI Lecture Series, 1988, 1989, 1990
ECT.
UTMSH, Department of Psychiatry, PGYI Lecture Series, 1988, 1989, 1990
MAOI's.
UTMSH, Department of Psychiatry, PGYI Lecture Series, 1988, 1989, 1990
Neuroendocrine Overview.
UTMSH, Department of Psychiatry, PGYI Lecture Series, 1988, 1989, 1990
Neuromodulators and Peptides: Basic Biology.
UTMSH, Department of Psychiatry PGYII Lecture Series, 1988, 1989, 1990
Neuroendocrine and Peptide Hypotheses of Psychiatric Disorders.
UTMSH, Department of Psychiatry PGYII Lecture Series, 1988, 1989, 1990
Anorexia Nervosa - Overview with Emphasis on Biology and Hospital Treatment.
UTMSH, Department of Psychiatry, PGYII Lecture Series, 1988, 1989, 1990
Overview of Anorexia Nervosa.
UTMSH, Department of Psychiatry, MSII Behavioral Science Course, 1988, 1989, 1990
The Efficacy and Safety of Three Doses of Sertindole Versus Three Doses of Haloperidol in Schizophrenic Patients.
American Academy of Clinical Psychiatrists, Fort Lauderdale, FL
Ris-63, Risperidone for Treatment of Behavioral Disturbances in Subjects with Dementia.
Janssen Pharmaceutica Research Foundation, Washington, DC
New Developments in Parkinson Medications.
Parkinson Foundation of Harris County
Clinical Experience with Intramuscular ziprasidone. Psychiatric Emergencies.
Pfizer Canada Inc
Depression/Anxiety, Patient Presentations and Treatment Approaches.
Smith Kline Beecham Pharmaceutical, Astroworld-Houston, Texas
New Medication for Psychotic Disorders.
Bay Area Alliance for the Mentally Ill
Evaluation and Management of the Acutely Psychotic Patient.
Emergency Nurses Association, 2000 Annual Meeting, Chicago, IL
The Evolving Nature of Mental Health Management.
Pfizer Ireland, Ltd
Ziprasidone Phase III Clinical Data Overview.
Waterford, Ireland
Diagnosis and Treatment of Bulimia.
Department of OB-GYN Grand Rounds, St. Joseph Hospital, Houston, Texas
Alcoholism and Affective Disorders - Two Case Presentations.
Department of Psychiatry, Grand Rounds, University of Texas Medical School-Houston
State-Related Changes in Plasma NE in Anorexia Nervosa.
LCS Section, NIMH Seminar
CSF 5H1AA and Prolactin Response to M-cpp in Anorexia Nervosa.
LCS Section, NIMH Seminar
Join now to see all